Transfusion and Apheresis Science
Volume 30, Issue 1 , Pages 9-15 , February 2004

The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy

  • Mutlu Arat

      Affiliations

    • Ankara University Faculty of Medicine, Ibni Sina Hospital, Department of Hematology, Sihhiye, Ankara 06100, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90-312-3103333x2121; fax: +90-312-3115474
    • ,
  • Önder Arslan

      Affiliations

    • Ankara University Faculty of Medicine, Ibni Sina Hospital, Department of Hematology, Sihhiye, Ankara 06100, Turkey
    • ,
  • Günhan Gürman

      Affiliations

    • Ankara University Faculty of Medicine, Ibni Sina Hospital, Department of Hematology, Sihhiye, Ankara 06100, Turkey
    • ,
  • Klara Dalva

      Affiliations

    • Hematodiagnostic Laboratory, Sihhiye, Ankara 06100, Turkey
    • ,
  • Muhit Özcan

      Affiliations

    • Ankara University Faculty of Medicine, Ibni Sina Hospital, Department of Hematology, Sihhiye, Ankara 06100, Turkey
    • ,
  • Aynur Uğur

      Affiliations

    • Akdeniz University Medical School, Department of Hematology, Kepez, Antalya, Turkey
    • ,
  • Osman Ilhan

      Affiliations

    • Ankara University Faculty of Medicine, Ibni Sina Hospital, Department of Hematology, Sihhiye, Ankara 06100, Turkey

Received 1 February 2003 ,Revised 1 March 2003 ,Accepted 1 May 2003.

References 

  1. Alyea E. Adoptive immunotherapy insights from donor lymphocyte infusions. Transfusion. 2000;40:393
  2. MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?. Br. J. Haematol. 2000;110:12–17
  3. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SA, Willemze R, et al.  Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest. 1995;96:877–883
  4. Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, et al.  Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br. J. Haematol. 1996;93:606–612
  5. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  6. Gürman G. Donor leukocyte infusion for the treatment of leukemia relapse after allogeneic hemapoietic cell transplantation with myeloablative conditioning. Turk. J. Haematol. 2000;17:171–181
  7. Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and non-malignant diseases in conjuction with allogeneic stem cell transplantation. J. Hematother. Stem. Cell. Res. 2002;11:265–276
  8. Roush KS, Hillyer CD. Donor lymphocyte infusion therapy. Transfus. Med. Rev. 2002;16(2):161–176
  9. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al.  Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 1994;330:1185–1191
  10. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995;333:1038–1044
  11. Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Çelebi H, et al.  Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy. 2001;3:253–260
  12. Demirer T, Ilhan O, Arat M, Genç I, Özcan M, Dalva K, et al.  CD41+ and CD42+ hematopoietic cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation. J. Clin. Apheresis. 2001;16:67–73
  13. Sato H, Shiobara S, Yasue S, Chuhjo T, Nakao S. Lymphocyte collection for donor leukocyte infusion form normal donors: estimation of the minimum processed blood volume and safety of the procedure. Vox Sang. 2001;81:124–127
  14. Sica S, Di Mario A, Salutari P, Rutella S, Chiusolo P, Rumi C, et al.  Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16(3):483–485
  15. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, et al.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J. Clin. Oncol. 2002;20(2):405–412
  16. Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS, et al.  Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer. 2002;94(1):18–24
  17. Flower ME, Leisenring W, Beach K, Riddell S, Radich JP, Higano CS, et al.  Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol. Blood Marrow Transplant. 2000;6:321–326
  18. Keil F, Haas OA, Fritsch G, Kahls P, Lechner K, Mannhalter C, et al.  Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood. 1997;89:3113–3117
  19. Dazzi F, Syzdlo M, Craddock C, Cross CP, Kaeda J, Chase A, et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67–71
  20. Anderlini P, Przepiorka D, Huh Y, Lauppe J, Miller P, Sundberg J, et al.  Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Brit. J. Haematol. 1996;93:940–942
  21. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High versus standard dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J. Clin. Oncol. 1999;17:2160–2172
  22. Körbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, et al.  Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J. Clin. Apheresis. 2001;16:82–87
  23. Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R, et al.  Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell––depleted peripheral blood stem cell transplants with delayed lymphocyte add-back. Brit. J. Haematol. 2001;115:95–104

PII: S1473-0502(03)00199-X

doi: 10.1016/j.transci.2003.05.004

Transfusion and Apheresis Science
Volume 30, Issue 1 , Pages 9-15 , February 2004

Article Tools

* Image Usage & Resolution